Last Update 05 Apr 26

Fair value Decreased 0.59%

NTRA: Molecular Residual Disease Leadership Will Drive Bullish Long Term Outlook

Analysts made a modest trim to the blended price target on Natera to about $259, reflecting slightly lower modeled revenue growth and profit margins. This adjustment comes even as several firms recently raised individual targets into the $215 to $300 range after updating their views on the company following Q4 results and new coverage initiations.

Analyst Commentary

Recent research updates on Natera cluster around a generally positive view of the company’s growth opportunities and execution, with some investors flagging valuation and guidance conservatism as key watchpoints. Price targets now span roughly US$215 to US$300, and ratings range from Equal Weight to Buy and Outperform.

Bullish Takeaways

Bullish analysts see Natera as an established player in women’s and organ health, with particular attention on its position in the molecular residual disease market, which they view as a key driver of long-term growth expectations and a support for premium valuation multiples.
Several bullish analysts raised price targets into the US$260 to US$300 range after reviewing Q4 results and updating models, indicating confidence in the company’s ability to execute against its current revenue and margin framework.
Some research cited Q4 gross margin performance as better than anticipated, which, in their view, strengthens the case for operating leverage over time if current trends in test mix and scale hold.
New coverage initiations with Buy ratings suggest that, for some, the current share price still leaves room relative to their assessed long term opportunity set, especially if the company continues to deliver against its 2026 outlook and beyond.

Bearish Takeaways

Bearish analysts, or those on the sidelines, highlight that Natera’s guidance is viewed as conservative, which they see as helpful for execution but a potential cap on near term upside if the market is already pricing in stronger outcomes.
The Equal Weight stance from some corners reflects a view that much of the expected growth may already be reflected in the valuation, leading to caution on risk or reward skew at current levels despite acknowledging operational strengths.
At least one major bank trimmed its price target from US$265 to US$250 after Q4, signaling a more measured stance on modeled revenue growth and profitability than some of the more bullish peers.
Competitive developments in areas like whole genome sequencing, including launches from rivals, are a background factor that cautious analysts continue to monitor when assessing how much to pay for Natera’s growth story.

What's in the News

Natera submitted a premarket approval application to the U.S. FDA for Signatera CDx as a companion diagnostic in muscle invasive bladder cancer, backed by the phase 3 IMvigor011 trial, which met its primary endpoint and supported Signatera guided use of atezolizumab (Tecentriq) (Key Developments).
The company announced the commercial launch of Zenith genomics, a whole genome sequencing assay for rare disease diagnostics, supported by long read confirmation and aimed at broad clinical adoption through Natera's U.S. provider network (Key Developments).
Natera and MyOme are collaborating on Zenith powered by MyOme, combining exome and genome testing with multi omic analysis to assess both DNA sequence and methylation patterns for rare disease evaluation (Key Developments).
Natera was added to the FTSE All World Index (USD), which can affect index linked ownership and visibility among global investors (Key Developments).
The company issued 2026 earnings guidance, indicating anticipated total revenue of US$2.62b to US$2.70b for the year (Key Developments).

Valuation Changes

Fair Value: Trimmed slightly from $260.65 to $259.11 per share.
Discount Rate: Adjusted marginally higher from 7.08% to 7.08%.
Revenue Growth: Moderated from 18.39% to 18.04% in the updated model.
Net Profit Margin: Reduced from 4.49% to 3.40% in the latest assumptions.
Future P/E: Raised from 294.3x to 389.3x, indicating a higher earnings multiple in the updated framework.

6 views

Key Takeaways

Growing adoption of molecular diagnostics and expanded clinical validation are driving revenue growth and increased reimbursement in core areas like oncology and organ health.
Investments in AI, automation, and new product launches are improving operational efficiency and positioning the company for future expansion in personalized medicine.
Heavy investment needs, regulatory hurdles, intense competition, and reimbursement challenges create persistent profitability and growth risks across Natera's core diagnostic markets.

Catalysts

About Natera

A diagnostics company, provides molecular testing services worldwide.What are the underlying business or industry changes driving this perspective?

Increasing adoption and acceptance of advanced molecular diagnostics is driving sustained volume and revenue growth across Natera's diversified portfolio, with significant headroom remaining for further penetration-particularly in oncology (Signatera) and organ health (Prospera); this will likely boost top-line revenue.
Expanding clinical validation through large-scale trials (DARE, IMvigor011, PROCEED/FIND, etc.) and broadening indications is expected to lead to further payer adoption and reimbursement, especially for new tumor types and expanded Medicare coverage; this should drive higher ASPs and gross margins.
Accelerated integration of AI and automation into diagnostic processes and revenue cycle management is providing greater operating leverage and efficiency, resulting in lower COGS and improving operating margins and net earnings over time.
Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, underpinning future revenue expansion.
Natera is managing operating expenses while scaling up (e.g., commercial hiring in oncology, AI technical staff), with near-term OpEx increases not yet impacting revenue but setting up a slingshot effect expected to drive meaningful revenue and margin improvements beginning in late 2025 and 2026.

Natera Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Natera's revenue will grow by 18.0% annually over the next 3 years.
Analysts assume that profit margins will increase from -9.0% today to 3.4% in 3 years time.
Analysts expect earnings to reach $129.1 million (and earnings per share of $0.91) by about April 2029, up from -$208.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $671.0 million in earnings, and the most bearish expecting $-208.0 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 390.5x on those 2029 earnings, up from -141.6x today. This future PE is greater than the current PE for the US Biotechs industry at 16.0x.
Analysts expect the number of shares outstanding to grow by 3.8% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.08%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Significant reliance on ongoing clinical trial success and future regulatory or reimbursement approvals for new indications (e.g., Medicare coverage of expanded cancer types, FDA approval for early cancer detection), introducing execution and regulatory risk-failure or delays could hinder revenue growth and margin expansion.
High and growing R&D and SG&A expenses, including major investments in new trials, expanded commercial team, and AI initiatives, may create persistent pressure on net margins and delay pathway to sustainable profitability, especially if incremental revenues from these investments take longer to materialize or underperform expectations.
Intensifying competition in core oncology and women's health markets, as well as threat of new entrants or disruptive technologies (such as whole genome sequencing or diagnostics from larger, better-capitalized players), may lead to average selling price (ASP) erosion and lost market share-putting downward pressure on revenue and gross margins over the long term.
Revenue "true-up" adjustments and collection efficiency improvements have contributed meaningfully to recent results, but these cash cycle improvements and payer mix dynamics may be difficult to sustainably replicate, leading to increased volatility and uncertainty in cash flow and earnings projections.
Broader industry risks-including increasing regulatory scrutiny (e.g., MolDX reimbursement policy changes), payer cost-containment pressures, and potential tightening of healthcare budgets due to economic headwinds-could restrict reimbursement rates or utilization of advanced diagnostics, negatively impacting long-term revenue growth and net earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $259.11 for Natera based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $300.0, and the most bearish reporting a price target of just $190.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.8 billion, earnings will come to $129.1 million, and it would be trading on a PE ratio of 390.5x, assuming you use a discount rate of 7.1%.
Given the current share price of $207.98, the analyst price target of $259.11 is 19.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Natera?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Clinical Advances and AI Will Drive Expansion Into New Diagnostic Markets